B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16

Benzinga · 1d ago
B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.